WS
TLSA icon

Wedbush Securities’s Tiziana Life Sciences TLSA Stock Holding History

Wedbush Securities’s Portfolio TLSA Stock Details TLSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,105
Closed -$57K – 970
2020
Q3 		$57K Buy
+17,105
New +$66.6K 0.01% 870

Other funds holding TLSA

HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return
CAAS
Capital Asset Advisory Services Williamston, Michigan $2.61B AUM 15.59% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Wedbush Securities's TLSA Position: Q4 2020 in Review

Wedbush Securities sold out of Tiziana Life Sciences (TLSA) in Q4 2020, closing a stake of 17,105 shares — an estimated $57K sold.

Wedbush Securities first reported a position in TLSA in Q3 2020 and held it in 1 quarter. The position peaked at $57K in Q3 2020. 24 funds tracked by Wall St. Rank hold TLSA as of Q4 2020.

  • Wedbush Securities reported no remaining Tiziana Life Sciences position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 17,105 Tiziana Life Sciences shares in Q4 2020, an estimated $57K.
  • Wedbush Securities first reported a position in Tiziana Life Sciences in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Tiziana Life Sciences position peaked at $57K in Q3 2020.
  • 24 funds tracked by Wall St. Rank held Tiziana Life Sciences as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.